The agrochemical field has long relied on animal models to evaluate the safety and efficacy of substances, but there’s a growing demand to adopt new alternative methods (NAMs) that can further the industry while reducing the need for animal testing. However, questions remain as to their long-term viability.

Join Robert Landsiedel, Vice President of Experimental Toxicology and Ecology, and Susanne Kolle, Research Coordinator of Experimental Toxicology and Ecology at BASF, as they explain the benefits of NAMs, how they comply with the 3Rs principle, and the role collaboration is playing to push NAMs as a viable alternative to animals.

Show Notes

Alternative Methods

AMAP Strategic Partnerships

Animals in Research

Modernizing Drug Development

Agrochemical Testing Service for Approvals

Chemical Testing Services

Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals

Charles River Laboratories, in Collaboration with MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives

How can genetic, geographic, and social considerations effect outcomes for Black women with cancer? To answer this question, I am joined this week by Dr. Lauren E. McCullough, Associate Professor in the Department of Epidemiology at the Rollins School of Public Health, and Julia Schueler, Research Director Therapeutic Area Lead Oncology for Charles River. Dr. McCullough is also one of the lead researchers for the American Cancer Society’s VOICES of Black Women initiative, which will track the health of participants over several years to gain insight into health considerations for Black women. For more information on how to enroll, please visit voices.cancer.org.

The N=1 Collaborative is changing the way we view drug development. Their specialty is creating customized therapies tailored to individual patients, paving the way for a unique approach that can leave long-lasting impacts on those with ultra-rare diseases.

Join us as Executive Director Hugh Hempel discusses the origins of N=1, the collaborative effort it takes to advance customized therapies down the pipeline, and what the future holds for the field of individualized medicine.

Show Notes

n=1 Collaborative

Rare Disease | Charles River

Rare Disease Research for Drug Development

Repurposing Drugs for Rare Disease

S4 E07: Free For Life: The Story of N-Lorem Foundation

Artificial intelligence and machine learning are launching a new era in drug development. By integrating these technologies, researchers can get their life-saving therapies to patients faster thanks to more accurate data and efficient processes.

Join us as Brian Roche, General Manager of Charles River’s integrated toxicology site in Kansas, as he discusses the advantages of using these advanced technologies, how their being leveraged across multiple platforms, and what role they play in shaping the future.

Show Notes

New Integrated Toxicology Site

Kansas Site

Unlocking the Promise of Integrated Toxicology: A Tour Through the Lab of the Future

Meeting at the Intersection of Technology and Scientific Innovation

David and Karen Kahn were overjoyed when they welcomed twins Amelia and Makenzie in 2010. However, it wasn't long before they realized their girls were different. Since getting their Batten disease diagnosis, they have worked tirelessly to find a treatment not only for their girls, but for kids around the world, with the help of researcher Dr. Michelle Hastings. Listen to their story now, and learn more about their mission at www.forebatten.org.

As researchers look for ways to reduce the need for animals in their studies, new alternative methods (NAMs) are an intriguing route to capture crucial safety data and help advance drug discovery and development – specifically, virtual control groups (VCGs).

Join Steve Bulera, CVP and Chief Scientific Officer for Safety Assessment and Toxicology at Charles River, as he discusses how VCGs can be a viable alternative to research models, what it would take for the industry to widely accept NAMs, and how they can revolutionize research for the future.

Show Notes

Virtual Control Groups

Sounds of Science E73: Virtual Control Groups

Modernizing Drug Development with Virtual Control Groups

Virtual Control Groups: A Data-Driven Novel Method

Revolutionizing the Future of Safety Studies

Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals

Dr. Jared Baeten, Senior Vice President of Clinical Development and Virology Therapeutic Area Head at Gilead Sciences, joins me to discuss the incredible advancements in pre-exposure prophylaxis (PrEP) treatments in honor of World AIDS Day. What if a twice yearly shot could replace a daily pill? Listen now to learn more!

As researchers continue to look for new ways to test therapeutics in vitro, the field of biomedical engineering is offering new microphysiological systems that can reduce the need for animal models. Hear from Jeffrey Borenstein, Director of the Biomedical Engineering Centre at Draper, as he explains how it works, ways to expedite its access, and the benefits they will ultimately bring to patients.

Show Notes 
 

The Coming of Age of Organ-on-a-Chip technology

Sounds of Science E76: Multi-Organ Chip Systems

Charles River Joins Consortium to Advance Organ-on-a-Chip Technology

Bold New Approached: The Future of Organoid Intelligence

Organoids Evolve from Academic Marvel to Industrial Tool